Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent-Reference-Cited by-同舟云学术

Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent

Published:2018 Issue:2 Volume:53 Page:117
ISSN:2287-979X
Container-title:Blood Research
language:en
Short-container-title:Blood Res

Author:

Sekiguchi Naohiro¹²,Hamano Airi³,Kitagawa Tomoko²,Kurihara Yuya¹,Ito Kenichi¹,Kurimoto Miwa¹,Watanabe Kozo³,Hirano Kazuhiko⁴,Noto Satoshi⁵,Yamada Kazuaki⁴,Takezako Naoki¹

Affiliation:

1. Hematology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan.

2. Clinical Research Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan.

3. Pharmaceutical Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan.

4. Laboratory and Pathology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan.

5. Clinical Oncology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan.

Publisher

The Korean Society of Hematology

Subject

Hematology

Link

https://synapse.koreamed.org/pdf/10.5045/br.2018.53.2.117

Reference30 articles.

1. Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

2. New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia

3. Waldenström macroglobulinemia

4. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome;Therapeutic Apheresis and Dialysis;2023-12-09

2. Temporal bone mucosal melanoma masquerading as otomastoiditis;Otolaryngology Case Reports;2022-09

3. Orphan Peripheral Neuropathies;Journal of Neuromuscular Diseases;2021-01-01

4. What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness;BLOOD RESEARCH;2019-06-30